Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer
This study is an open-label, single center, and a single arm phase II study to evaluate the clinical response and safety of perioperative S-1 plus docetaxel. Perioperative chemotherapy is composed of 3 cycles of preoperative S-1/docetaxel and 3 cycles of postoperative S-1/docetaxel.Chemotherapy regimen:

* S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)
* Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8
Stomach Neoplasms
DRUG: S-1,Docetaxel
To evaluate the clinical responses to preoperative S-1 plus docetaxel, During chemotherapy
the clinical downstaging,the pathologic responses, toxicity profile,the disease-free survival,overall survival,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics and the difference in pharmacokinetics between before and after gastrectomy, During study period
This study is an open-label, single center, and a single arm phase II study to evaluate the clinical response and safety of perioperative S-1 plus docetaxel. Perioperative chemotherapy is composed of 3 cycles of preoperative S-1/docetaxel and 3 cycles of postoperative S-1/docetaxel.Chemotherapy regimen:

* S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)
* Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8